'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Liver Fibrosis Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Liver Fibrosis 30
Nov 13, 2016: TRACON Pharmaceuticals Presents Clinical and Preclinical Data from Models of NASH and Liver Fibrosis at the 2016 AASLD Annual Meeting 30
Oct 12, 2016: ProMetic PBI-4050 Significantly Reduces Liver Fibrosis in Patients with Alstrom Syndrome 30
Sep 27, 2016: Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis 31
Clinical Trial Profile Snapshots 33
Appendix 117
Abbreviations 117
Definitions 117
Research Methodology 118
Secondary Research 118
About GlobalData 119
Contact Us 119
Disclaimer 119
Source 120
List of Tables
Liver Fibrosis Therapeutics, Global, Clinical Trials by Region, 2016* 6
Liver Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Liver Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Liver Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Liver Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Liver Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Liver Fibrosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Liver Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Liver Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Liver Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Liver Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Liver Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Liver Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Liver Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Liver Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
List of Figures
Liver Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Liver Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Liver Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Liver Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Liver Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Liver Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Liver Fibrosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Liver Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Liver Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Liver Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Liver Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Liver Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Liver Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Liver Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Liver Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 118